Last Updated: 15/10/2025
World’s first: Research to develop a next-generation viral vector vaccine against P. falciparum and P. vivax
Objectives
The purpose of this study is to develop a bivalent vaccine that exerts high “infection protection” and “transmission prevention” effects against both Plasmodium falciparum and Plasmodium vivax using the proprietary LC16m8Δ/AAV vaccine platform and evaluate its efficacy in a mouse model.
Principal Institution
Principal Investigators / Focal Persons
Rationale and Abstract
A bivalent vaccine has already been successfully produced, and vaccine-immunized mice have been confirmed to induce high specific antibody titers for a long period of time. New mouse model experiments are planned to start in 2024 to evaluate the infection prevention effect, and immune mouse serum will be brought to Manaus, Brazil to evaluate the transmission prevention effect.
External reference
Date
Apr 2024 — Mar 2027
Total Project Funding
$20,598
Funding Details
Project Site
Related Resources
